{
    "clinical_study": {
        "@rank": "100662", 
        "brief_summary": {
            "textblock": "Hypothesis: The UAS Immunotherapy protocol is efficacious and at least as efficacious as\n      protocols described in the Allergy literature."
        }, 
        "brief_title": "The Efficacy & Safety of the UAS Immunotherapy Protocol", 
        "completion_date": {
            "#text": "September 2012", 
            "@type": "Actual"
        }, 
        "condition": "Perennial Allergic Rhinitis With Seasonal Variation", 
        "condition_browse": {
            "mesh_term": [
                "Rhinitis", 
                "Rhinitis, Allergic, Perennial"
            ]
        }, 
        "detailed_description": {
            "textblock": "Patients will be assessed for efficacy of the immunotherapy protocol by completing\n      Consented-IRB approved clinical, medication, quality of life survey questions comparing\n      current status while on therapy in contrast to 12 months before the inception of therapy."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Allergic rhinitis between 18 and 65 years old who have chosen to undergo\n             immunotherapy.\n\n        Exclusion Criteria:\n\n          -  No beta blocker use,\n\n          -  no pregnancy,\n\n          -  no systemic steroids,\n\n          -  no severe asthma/copd,\n\n          -  no severe collagen vascular disorders,\n\n          -  no neoplastic or uncontrolled seizure activity,\n\n          -  no previous anaphylaxis, no significant cardiovsacular disease."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Patients with allergic rhinitis pre and post immunotherapy (1 to 2 years)."
            }
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "September 10, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01699659", 
            "org_study_id": "UAS protocol #1", 
            "secondary_id": "UAS protocol #1"
        }, 
        "intervention": {
            "description": "allergy shots", 
            "intervention_name": "allergen immunotherapy", 
            "intervention_type": "Other", 
            "other_name": "allergy shots"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Allergic Rhinitis", 
            "Allergen Immunotherapy"
        ], 
        "lastchanged_date": "October 3, 2012", 
        "location": {
            "facility": {
                "address": {
                    "city": "San Antonio", 
                    "country": "United States", 
                    "state": "Texas", 
                    "zip": "78216"
                }, 
                "name": "UAS"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "1", 
        "official_title": "The Efficacy and Safety of the United Allergy Service (UAS) Immunotherapy Protocol", 
        "other_outcome": {
            "description": "QOL scores will be calculated after one to 2 years of therapy and contrasted with QOL reflecting status 12 months prior to initiation of therapy.", 
            "measure": "Quality of Life (QOL) scores", 
            "safety_issue": "No", 
            "time_frame": "Assessment contrasts current status (at 1 to 2 years of therapy) to a point 12 months prior to the onset of therapy"
        }, 
        "overall_official": {
            "affiliation": "United Allergy Services", 
            "last_name": "Frederick M Schaffer, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "September 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Enrolled patients completed surveys pertinent to symptom scores, contrasting current status on immunotherapy compared (by recall) to a 12 month time point prior to initiation of therapy.", 
            "measure": "change in symptom scores from 12 months before therapy initiation in contrast to determination during 1 to 2 years of therapy (retrospective).", 
            "safety_issue": "No", 
            "time_frame": "Assessment contrasts current status (at 1 to 2 years of therapy) to a point 12 months prior to the onset of therapy."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01699659"
        }, 
        "responsible_party": {
            "investigator_affiliation": "United Allergy Services", 
            "investigator_full_name": "Frederick M. Schaffer, MD", 
            "investigator_title": "Chief Medical Officer", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Aggregate Medication and Symptom surveys were compared to determine changes from a 12 month time point prior to inception of therapy to current time point of 1 to 2 years of therapy.", 
            "measure": "Changes in medication plus symptom aggregate score.", 
            "safety_issue": "No", 
            "time_frame": "Assessment contrasts current status (at 1 to 2 years of therapy) to a point 12 months prior to the onset of therapy."
        }, 
        "source": "United Allergy Services", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "United Allergy Services", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2012", 
        "study_design": "Observational Model: Case-Only, Time Perspective: Retrospective", 
        "study_type": "Observational", 
        "verification_date": "October 2012"
    }
}